An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
Price : $35 *
At a glance
- Drugs Anti-PSCA monoclonal antibody (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Agensys
- 31 Aug 2018 Biomarkers information updated
- 10 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.